Cellares $257M, Regenxbio Hold, Skyhawk Huntington’s
High-conviction capital is flooding cell therapy infrastructure as Cellares secures a $257M Series D to industrialize manufacturing. Meanwhile, a brain tumor discovery in a Regenxbio trial raises fresh questions about AAV gene therapy’s long-term safety profile, and Skyhawk’s oral Huntington’s drug shows the best mHTT reduction ever demonstrated in patients.
The investment logic in cell therapy is shifting from “discovery-first” to “manufacturing-first.” BlackRock’s co-lead on Cellares’ Series D signals that institutional capital now views manufacturing bottlenecks—not science—as the primary barrier to CAR-T scalability. At the same time, the Regenxbio hold reminds investors that gene therapy’s long-tail safety risks remain unresolved, even as the FDA deepens myeloma’s standard of care with the first quadruplet regimen approved on MRD-negativity.
What To Watch
Cell Therapy “Industrial Revolution”
The Cellares Series D, backed by BlackRock and Intuitive Ventures, signals a pivot from “discovery-first” to “manufacturing-first” investment logic as high costs choke commercial scaling. With Bristol Myers Squibb and Gilead’s Kite already hooked into automated IDMO infrastructure, the competitive question shifts from “can we make CAR-T work?” to “can we make CAR-T scale?”
Gene Therapy Safety Scrutiny
The FDA clinical hold on Regenxbio gene therapies following a brain tumor observation in a 5-year-old patient is a localized blow that may heighten regulatory sensitivity across the entire AAV-delivery landscape. Preliminary analysis detected vector genome integration linked to proto-oncogene overexpression—exactly the mechanism the field has long feared.
Small Molecule RNA-Modulation
Skyhawk’s 9-month Huntington’s data for SKY-0515 marks a critical milestone for oral splice modulators, showing the largest mHTT reduction demonstrated by any therapeutic tested in patients. Watch for competitive read-through on PTC Therapeutics and the broader RNA-modulation thesis.
Top Story: Cellares Raises $257M to Scale Automated “Smart Factories”
What Happened: South San Francisco-based Cellares closed a $257 million Series D today to globalize its automated cell therapy manufacturing platform. The round was co-led by BlackRock and Eclipse, with strategic participation from T. Rowe Price, Baillie Gifford, Duquesne Family Office, Intuitive Ventures, EDBI, and Gates Frontier. Total capital raised now exceeds $612 million.
Why It Matters: This financing addresses the “manufacturing bottleneck” that has historically limited CAR-T therapies to small, centralized patient pools. By attempting to match the output of 10 conventional CDMO facilities with a single automated Smart Factory, Cellares is moving to make cell therapy a high-volume, lower-cost reality. The company’s Cell Shuttle platform already holds FDA Advanced Manufacturing Technology designation—a regulatory signal that could support expedited review for partners incorporating the technology.
📊 Cellares Series D Deal Structure
Round: Series D | $257 million
Lead Investors: BlackRock, Eclipse
Strategic Participants: Intuitive Ventures, Gates Frontier, T. Rowe Price, Baillie Gifford
Total Raised: $612 million
Key Partnership: $380M global manufacturing agreement with Bristol Myers Squibb
IPO Timeline: Q4 2027 (per Endpoints News)
Commercial Launch: Clinical manufacturing H1 2026; commercial-scale 2027
Executive Impact: Bristol Myers Squibb and Gilead’s Kite already have hooks into this tech; other cell therapy leaders must now decide whether to build bespoke manual capacity or outsource to automated IDMO models to preserve future margins. The investment thesis is shifting from “can we cure cancer with cell therapy?” to “can we deliver cures at scale?” Cellares is betting the answer requires factory automation, not headcount expansion.
Safety Signal: Regenxbio Gene Therapies Halted
⚠️ FDA Clinical Hold on RGX-111 and RGX-121
What Happened: The FDA placed clinical holds on Regenxbio’s RGX-111 (Hurler syndrome) and RGX-121 (Hunter syndrome) gene therapies after a brain tumor was discovered in a 5-year-old patient who had received RGX-111 four years earlier. The child was asymptomatic; the tumor was found during routine MRI surveillance.
The Mechanism Concern: Preliminary genetic analysis detected an AAV vector genome integration event associated with overexpression of PLAG1, a proto-oncogene known to be susceptible to chromosomal rearrangements. Causality has not been established, but the finding raises the specter of insertional mutagenesis—the same theoretical risk that has shadowed AAV gene therapy since its inception.
Broader Implications: Regenxbio shares fell ~30% on the news. No similar events have been reported in nine other RGX-111 patients or 32 RGX-121 patients. However, the FDA’s decision to extend the hold to RGX-121 “citing similarities in products, study populations, and shared risk” signals regulatory caution that could affect AAV programs across the industry. A PDUFA decision for RGX-121 was scheduled for February 8, 2026—now at risk.
Competitive Read: Denali Therapeutics’ tividenofusp alfa, a non-gene-therapy approach to Hunter syndrome, is tracking toward an April 2026 FDA decision. Jefferies analysts noted DNLI could receive earlier approval given RGNX’s regulatory setback.
Oncology & Rare Disease
Darzalex Faspro: First Quadruplet Regimen Based on MRD Endpoint
J&J / Janssen (FDA Approval): The FDA approved Darzalex Faspro plus VRd (bortezomib, lenalidomide, dexamethasone) for newly diagnosed multiple myeloma patients ineligible for transplant—the 12th indication for the Darzalex franchise.
Significance: This is the first quadruplet regimen approved using Minimal Residual Disease (MRD) negativity as a primary endpoint (52.3% vs. 34.8% for triplet in the CEPHEUS trial), effectively moving the clinical goalpost from “remission” to “molecularly undetectable disease.” The approval signals FDA’s growing comfort with MRD as a meaningful endpoint in hematologic malignancies.
Acrivon Therapeutics: 39% ORR Fuels Phase 3 Plans
Pivotal Intent: Acrivon announced a 39% overall response rate in its Phase 2b trial for ACR-368 (prexasertib) in biomarker-positive endometrial cancer, with 52% confirmed ORR in serous subtype patients with ≤2 prior lines. The company has submitted a Phase 3 confirmatory protocol to FDA for ACR-368 plus anti-PD-1 in frontline pMMR endometrial cancer. Global trial readiness expected mid-2026.
BioNTech: mRNA Immunotherapy Gets Fast Track
FDA Fast Track: BioNTech received Fast Track designation for BNT113, an mRNA immunotherapy encoding HPV16 oncoproteins E6 and E7, for HPV16+ head and neck cancer expressing PD-L1. The designation is based on preliminary data from the Phase 2/3 AHEAD-MERIT trial evaluating BNT113 plus pembrolizumab. No HPV-targeted treatments are currently approved for this indication, leaving patients with median OS of 20.7 months on standard of care.
Clinical & Research Updates
Skyhawk Therapeutics: Huntington’s Drug Shows Best-in-Class mHTT Lowering
📊 SKY-0515 Nine-Month Data
cUHDRS Change: +0.64 points (improvement) vs. -0.73 expected (worsening)
mHTT Reduction: 62% at 9mg dose (largest demonstrated in patients)
PMS1 mRNA Reduction: 26% (additional disease-modifying target)
Patients Dosed: >90 across Phase 1 and Phase 2/3 FALCON-HD
Trial Expansion: FALCON-HD now enrolling worldwide
Modality: Oral small molecule RNA splicing modulator
Why It Matters: SKY-0515 achieved a 1.37-point divergence from natural history on cUHDRS—the first oral huntingtin-lowering therapy to demonstrate functional improvement rather than just biomarker reduction. The dual mechanism (HTT + PMS1 lowering) may provide additive benefit by both reducing toxic protein and slowing somatic CAG repeat expansion. Full Phase 1 results expected mid-2026.
PDS Biotech: IL-12 Immunocytokine in Prostate Cancer
NCI-Led Phase 2: PDS Biotech presented preliminary results for PDS01ADC plus docetaxel in 3rd-line metastatic castration-resistant prostate cancer, showing median progression-free survival of 9.6 months (range: 4.3–32.2) and 40% median PSA decline. Six of 16 patients achieved >50% PSA reduction. This represents the first clinical trial of an immunocytokine combined with docetaxel in prostate cancer.
Corporate Developments
Halozyme Acquires Surf Bio for $400M
M&A: Halozyme announced the acquisition of Surf Bio ($300M upfront, up to $100M in milestones) to expand its high-concentration drug delivery portfolio. Surf Bio’s hyperconcentration technology enables formulations up to 500 mg/mL, potentially allowing single-shot auto-injector delivery of biologics currently requiring IV infusion. The deal extends Halozyme’s IP runway into the mid-2040s and positions the company to defend royalty streams as subcutaneous conversion becomes a standard competitive defense against biosimilars.
Eli Lilly: $1.12B Hearing Loss Gene Editing Pact
Strategic Pact: Lilly signed a global collaboration with Germany-based Seamless Therapeutics worth over $1.12 billion in upfront payment, R&D funding, and potential milestones (excluding royalties). Seamless will design programmable recombinases to correct mutations in hearing loss genes; Lilly receives exclusive license to develop and commercialize. This continues Lilly’s aggressive expansion into genetic medicines following the Verve Therapeutics ($1.3B) and Rznomics ($1.3B) acquisitions in 2025.
Danaher: Bioprocessing Strength Continues
Q4 Earnings: Danaher reported Q4 revenue of $6.84B (+4.5% YoY) with continued strength in bioprocessing and improved momentum in diagnostics and life sciences. CEO Rainer Blair highlighted high-single-digit bioprocessing growth expected for 2026, driven by consumables. Full-year 2026 guidance: 3-6% core revenue growth, adjusted EPS $8.35-$8.50. The results signal stabilization in bioprocessing demand—a key bellwether for the broader R&D services sector.
Policy & Public Health
Biogen Litifilimab: Breakthrough for Cutaneous Lupus
FDA Breakthrough Status: Granted to Biogen’s litifilimab for cutaneous lupus erythematosus (CLE), a disease with no currently approved targeted therapies. The first-in-class BDCA2-targeted monoclonal antibody is designed to reduce type-I interferon production by plasmacytoid dendritic cells. Phase 3 AMETHYST data expected 2027. CLE affects 70-85% of lupus patients and can cause permanent scarring and disfigurement.
Otsuka Centanafadine: Priority Review for ADHD
FDA Priority Review: The FDA accepted Otsuka’s NDA for centanafadine with a July 24, 2026 PDUFA date. If approved, it would be the first-in-class NDSRI (norepinephrine, dopamine, serotonin reuptake inhibitor) for ADHD—a novel triple mechanism addressing all three monoamine systems in a once-daily extended-release formulation. Four Phase 3 trials demonstrated significant symptom improvement versus placebo across children, adolescents, and adults.
Related BioMed Nexus Coverage
Cell & Gene Therapy
- CAR-T Manufacturing Bottleneck: Why Scale Is the New Science
- AAV Safety Signals: What the Regenxbio Hold Means for the Field
- Intellia MAGNITUDE Update: CRISPR Platform Clears Safety Hurdle
Oncology & Hematology
- MRD-Negativity as Endpoint: FDA’s Growing Comfort Level
- Darzalex Franchise: Building the Myeloma Standard of Care
- HPV-Targeted Cancer Therapies: BioNTech, PDS Biotech, and the Pipeline
Neurology
- Huntington’s Disease: Oral vs. Intrathecal Approaches
- RNA Modulation Platforms: Skyhawk, PTC, and the Competitive Landscape
Frequently Asked Questions
What is Cellares’ Cell Shuttle technology?
Cell Shuttle is a fully automated, closed-system platform for end-to-end cell therapy manufacturing. It integrates all production steps into a single “factory-in-a-box,” claiming 10x higher throughput and lower per-patient costs compared to conventional CDMO facilities.
Why did the FDA place a hold on Regenxbio’s RGX-121 when the tumor was found in RGX-111?
The FDA cited “similarities in products, study populations, and shared risk between the clinical studies.” Both are AAV-delivered gene therapies for MPS lysosomal storage disorders, and the potential insertional mutagenesis mechanism could theoretically apply to both.
What is MRD-negativity and why is it significant for myeloma?
Minimal Residual Disease negativity means no detectable cancer cells at the molecular level—typically less than 1 cancer cell per million. The Darzalex Faspro approval using MRD as primary endpoint validates this as a meaningful surrogate for long-term outcomes, potentially accelerating future trial designs.
How does SKY-0515 differ from previous Huntington’s therapies?
SKY-0515 is an oral small molecule that modulates RNA splicing to reduce both huntingtin protein and PMS1 (a driver of CAG repeat expansion). Previous approaches used intrathecal antisense oligonucleotides. The 62% mHTT reduction is the largest demonstrated in patients by any therapeutic.
What is Halozyme’s strategy with the Surf Bio acquisition?
Halozyme is diversifying beyond its ENHANZE enzyme platform into hyperconcentration technologies that enable high-dose biologics in small-volume auto-injectors. This extends royalty opportunities into the 2040s and positions the company to convert IV drugs to subcutaneous delivery.
What makes centanafadine different from existing ADHD medications?
Centanafadine is a triple reuptake inhibitor targeting norepinephrine, dopamine, and serotonin—the first NDSRI for ADHD. Unlike stimulants, it showed low abuse potential in clinical trials while demonstrating onset of action by week 1, faster than typical non-stimulants.
Why is BioNTech pursuing HPV-targeted cancer immunotherapy?
HPV16 drives approximately 90% of oropharyngeal cancers (a head and neck cancer subtype), yet no HPV-targeted treatments are approved. BNT113 encodes viral oncoproteins to stimulate tumor-specific immune responses—diversifying BioNTech’s mRNA platform beyond COVID vaccines.
What does Eli Lilly’s hearing loss deal signal about their strategy?
Lilly is aggressively building a genetic medicines franchise. The Seamless deal (recombinases), Verve acquisition (base editing), Rznomics (RNA editing), Adverum, and MeiraGTx partnerships demonstrate a platform-agnostic approach to gene therapy—acquiring diverse technologies rather than betting on a single modality.
What is cutaneous lupus and why does it need new treatments?
Cutaneous lupus erythematosus (CLE) is a chronic autoimmune skin disease affecting 70-85% of lupus patients, causing rashes, scarring, and hair loss. No targeted therapies are currently approved; treatment relies on topical steroids and antimalarials with limited efficacy.
How does Danaher’s bioprocessing outlook affect the broader sector?
Danaher’s Cytiva unit is a bellwether for biopharma manufacturing demand. The company’s projection of high-single-digit bioprocessing growth for 2026 suggests the post-pandemic destocking cycle is ending and biotech R&D activity is stabilizing—positive for CDMOs, equipment suppliers, and capital investment.
Stay Ahead of the Market
The investors and executives reading this article at 6 AM will act on these insights before the market opens. The question is whether you’ll be among them—or reacting to moves others made first.
BioMed Nexus Daily — Free
Join 12,000+ healthcare professionals
The essential morning briefing for biotech, medtech, and pharma. Delivered before market open, every trading day.
- Market-moving news and overnight developments
- Key catalysts and earnings on deck
- Regulatory decisions and clinical data releases
No spam. Unsubscribe anytime. Read by analysts at Goldman, Morgan Stanley, and JP Morgan.
BioMed Nexus Pro — $395/year
For serious investors and industry operators
Institutional-grade analysis that gives you an edge. The same frameworks used by hedge funds and BD teams.
Everything in Free, plus:
- Full Weekday Pro Intelligence (Monday–Friday)
- 30-Day Catalyst Watch & Risk Outlook Matrix
- Tomorrow’s Top 5 Near-Term Catalysts Across Biotech & Medtech
- Trial Decoder, plain-English reads on key clinical data
- Money Flow Monday, financings, BD moves, and quiet deal activity
- Deal Heat Tracker with professional, institutional-grade analysis
Annual billing with a single invoice, easy to expense as a research or professional subscription.
“BioMed Nexus is the first thing I read every morning. It’s replaced three other newsletters.”
— Director of Business Development, Top 10 Pharma
BioMed Nexus provides daily intelligence for leaders in biotech, medtech, and pharma. This daily brief is intended for context, not investment recommendation.
